Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR, NMPA) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Radiofrequency Ablation for Aldosterone-producting Adenoma in Patients With Primary Aldosteronism

NCT: NCT02756754 · COMPLETED

NCT IDNCT02756754
StatusCOMPLETED
Start Date2016-11-07
Completion2019-05-10

Brief Summary

The aim of the study is to evaluate the novel use of adrenal radiofrequency ablation on a prospective cohort of patients with primary aldosteronism and unilateral adrenal adenoma concerning the efficacy on blood pressure control. The safety of the procedure is one of the secondary outcomes.

Frequently Asked Questions

What is Radiofrequency Ablation for Aldosterone-producting Adenoma in Patients With Primary Aldosteronism?

Radiofrequency Ablation for Aldosterone-producting Adenoma in Patients With Primary Aldosteronism is a clinical trial registered under NCT02756754. Current status: COMPLETED.

What is the status of NCT02756754?

The current status of NCT02756754 (Radiofrequency Ablation for Aldosterone-producting Adenoma in Patients With Primary Aldosteronism) is: COMPLETED.

When did Radiofrequency Ablation for Aldosterone-producting Adenoma in Patients With Primary Aldosteronism start?

Radiofrequency Ablation for Aldosterone-producting Adenoma in Patients With Primary Aldosteronism started on 2016-11-07.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑